Ginkgo Bioworks
Ginkgo Bioworks raises $350M Series E at $4.9B valuation
Quick Facts
Ginkgo Bioworks: Series E Funding Round
Ginkgo Bioworks has successfully raised $350M in Series E funding, reaching a valuation of $4.9B.
Company Overview
Synthetic biology and organism engineering
Funding Details
The Series E round was led by Baillie Gifford, with participation from ARK Investment Management.
Company Information
- Headquarters: Boston, MA
- Founded: 2008
- Employees: 600+
- Category: Biotech
Investment
Ginkgo Bioworks plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series E
- ARK Investment Management: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
